DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04583358 (ClinicalTrials.gov)	August 26, 2020	16/9/2020	Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)	A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects With Moderate to Severe Ulcerative Colitis (LOMBARD)	Ulcerative Colitis	Drug: AMT-101 (oral);Other: Placebo (oral)	Applied Molecular Transport	NULL	Recruiting	18 Years	80 Years	All	102	Phase 2	United States;Canada;Georgia;Hungary;Moldova, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04583358
(ClinicalTrials.gov)

August 26, 2020

16/9/2020

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects With Moderate to Severe Ulcerative Colitis (LOMBARD)

Ulcerative Colitis

Drug: AMT-101 (oral);Other: Placebo (oral)

Applied Molecular Transport

NULL

Recruiting

18 Years

80 Years

All

102

Phase 2

United States;Canada;Georgia;Hungary;Moldova, Republic of